Migraineguard ™ Supplement Reduces the Severity and Frequency of Migraine , a Randomized, Placebo-controlled, Double-blind, Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 2
- 主要终点
- Number of patient experiencing migraine attack reduction by at least 50 percent in one month .
研究概览
简要总结
Numerous treatments have been recommended for the prevention of migraine. The purpose of this randomized double-blind placebo controlled trial was to assess the efficacy of MIGRAINEGUARD ™ supplement by Herbacure Natural containing a combination of COQ10 , magnesium, riboflavin ,feverfew , Skullcap and black pepper as prophylactic treatment for migraine.
详细描述
Our team will assess MIGRAINEGUARD ™ , a migraine prevention supplement marketed Herbacure Natural for individual suffering from multiple migraine attacks in one month . The purpose of this 7-months , randomized, double-blind, placebo controlled study is to evaluate the efficacy and safety of MIGRAINEGUARD ™ produced by Herbacure Natural , A Canadian company based in Vancouver , BC , in reducing migraine headache severity and frequency of attacks compared to placebo when used every day, as a preventative solution for migraine and to assess and monitor the safety of its usage for adverse effects.
The primary end-point is the severity and the frequency reduction of migraine attacks. The secondary end-points will be the existence of adverse reaction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult aged 18 to 65 years Female and Male
- •Based on IHS criteria ,are diagnosed with migraine (criteria of the International Classification of Headaches Disorders)
- •Individuals with minimum of 3 severe to extreme migraine attacks during the last 3 months .
- •Generally in good health
排除标准
- •Individuals taking any preventive treatment for migraine
- •Excessive usage of painkillers
- •Cancer & Head injury and trauma
- •Any medical condition that may impact the validity of collected information
- •Previous usage of Botox within 6 months of study
- •Last week usage of triptans
结局指标
主要结局
Number of patient experiencing migraine attack reduction by at least 50 percent in one month .
时间窗: 7 months
Number of patient experiencing migraine attack reduction by at least 50 percent in one month . Migraineurs with 50 percent migraine attack decrease are considered "Responders" to supplement.
Severity of migraine headache reduction after & Months
时间窗: 7 Months
Reduction of Migraine severity After 7 months of supplementation
次要结局
- Adverse Reactions(7 months)